New Sugar-Based tracer could spot brain tumors on SPECT scans
NCT ID NCT04288518
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a radioactive sugar-like tracer called 99mTc-1-thio-D-glucose to see if it can make brain tumors visible on SPECT scans. Sixteen adults with primary or recurrent brain tumors received one injection, then had scans at several time points. Researchers measured how the tracer spread in the body and compared the images to MRI and PET scans. The goal was to see if this tracer is safe and could be a simpler, cheaper alternative for brain tumor imaging.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Technetium-99m labeled 1-Thio-D-Glucose (99mTc-1-thio-D-glucose)
What this could lead to
If successful, this could provide a more accessible imaging method for detecting brain tumors using SPECT instead of PET.
What could go wrong
This is a very small, early-phase study (16 people) focused on imaging, not treatment. The tracer may not prove accurate enough for routine use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
TomskNRMC
Tomsk, Russia